Dr. Tracey Evans on Chemotherapy for the Elderly Patient

Video

Tracey Evans, MD, Associate Professor of Clinical Medicine University of Pennsylvania Health System, discusses how to determine which patients will benefit from chemotherapy.

Tracey Evans, MD, Associate Professor of Clinical Medicine University of Pennsylvania Health System, discusses how to determine which patients will benefit from chemotherapy.

The elderly, who are defined as those aged 65 or older, have historically not been considered good candidates for chemotherapy, Evans says. Because of this, they are often denied chemotherapy or given more gentle chemotherapy regimen.

Evans says more recent studies have shown that physiologic age is more important than chronological age. While elderly patients tend to experience more toxicities with chemotherapy​, they see the same survival benefit from platinum-based doublet chemotherapy as non-elderly patients.

Related Videos
Nikhil A. Gopal, MD
Kara N. Maxwell, MD, PhD
Ruben Olivares, MD
Scott Kopetz, MD, PhD, FACP
Rita Nanda, MD
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Lauren E. Nye, MD, breast medical oncologist, clinical medical director, Breast Cancer Prevention, the University of Kansas Cancer Center
Joseph G. Jurcic, MD
Zeynep Eroglu, MD
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute